reason report
strong dupi break profit investor pt
bottom line yesterday earn beat strong dupix
dupi eylea sale updat model increas revenu
estim long-term
estim unchang forecast higher expens
come year given portfolio invest
reason pro forma ep estim reduc
later year base chang model prevail peer
compani multipl reduc price target maintain
outperform rate stock adjust revenu forecast
remain consensu later year
pro-forma ep estim consensu
period less expect eylea prove durabl
skeptic fear dupix rapidli break
massiv product fair consensu well
expect regeneron still hasnt answer question
portfolio substanti potenti beyond dupix sinc
pessimist expect half-shar profit dupix
less match eros eylea regeneron would investor believ
immuno-oncolog io franchis contribut meaning
top-lin growth quarter libtayo doesnt suggest
rival categori leader anytim soon believ
simpler financi report simplif relationship sanofi
relief refer price concern could see stock
recov signific valu later year ultim novel drug
bispecif advanc pivot trial result
justifi stock return former lofti perch sector
eylea dupix deliv strong revenu beat regeneron
legaci product eylea continu strong durabl growth
us vs consensu vs us yoy howev
partial benefit temporari shortag compound avastin
certain geograph area appear end end
quarter accord regeneron due strong perform
dupix sanofi-regeneron antibodi allianc reach posit profit
regeneron share profit look ahead
compani enjoy continu high singl digit low doubl digit
revenu growth eylea least year-end dupix
juggernaut continu new indic drive increment
revenu us european market beyond
cautious optimist partnership profit
ramp rapidli provid cours compar ramp
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
regeneron continu suffer mix prospect
commerci product praluent offici bust libtayo remain
small among question potenti prospect
previous featur pipelin program antibodi
unclear clinic path forward new total revenu forecast
consensu higher consensu
updat ep estim higher recent
consensu higher base
chang reiter outperform rate regn stock
decreas price target
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success first truli
novel medicin dupix allerg diseas first product eylea continu surpris
investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab remain posit eylea expect continu grow
lose market share emerg competitor novarti
seem like approv excit aspect compani next wave
innov antibodi notabl dupix approv adult atop dermat
asthma like receiv label expans multipl allerg diseas indic
expect dupix dupilumab gener revenu signific upsid
indic longer term regeneron wholli own antibodi could contribut
meaning revenu earn growth period current compani
invest mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv
period profit antibodi collabor sanofi begin accumul
top-lin growth driven us eylea global dupix sale
total revenu consensu
estim regeneron eylea surprisingli deliv outstand result
us market y/i q/q vs us vs consensu manag
comment continu growth us market driven favor demograph
share gain product share categori ex-u
eylea sale larg in-lin estim consensu strong
us sale benefit temporari shortag compound avastin certain geograph
area appear end end quarter regeneron expect launch
eylea pre-fil syring us shortli base pdufa date plan
initi higher concentr formul aflibercept regimen end
dupix sale doubl yoy increas nearli compar
manag disclos dupix trx grew q/q compar weekli nbrx
averag patient prior quarter manag indic growth
dupix driven continu expans ad current penetr adult
ad launch new indic age group specif asthma adult adolesc
atop dermat asthma indic compani comment new-to-brand
dupix patient biolog nave switch biolog therapi
accord sanofi regeneron q/q nbrx growth driven increas use
dermatologist q/q allergist q/q pulmonologist q/q
kevzara sale consensu estim libtayo
sale consensu estim total collabor
revenu regeneron partnership sanofi bayer teva
quarter higher consensu estim primarili driven
sanofi antibodi collabor revenu
higher product sale collabor profit deliv ep upsid
regeneron report total non-gaap oper expens consensu
estim increas spend mainli occur
 oper margin quarter beat us consensu
improv compar sg line estim slightli higher
encouragingli compani appear final deliv leverag sg
expens revenu increas regeneron report higher non-gaap tax rate
compar consensu forecast still deliv substanti ep beat
manag comment higher non-gaap tax rate mainli due alnylam
million up-front exclus non-gaap earn compani guid full-year
non- tax rate higher full-year effect tax rate combin
compani report pro forma ep consensu
estim
regeneron updat guidanc earn call manag tighten
prior expens guidanc increas lower end non-gaap
unreimburs increas lower rang
non-gaap sg guidanc reduc
capit expenditur commercialization-rel expens remain
rel unchang decreas top end effect tax
rate guidanc unchang non-gaap unreimburs guidanc
prior estim recent consensu
non-gaap sg guidanc bracket consensu estim
tax rate guidanc consensu estim capital-expenditure
guidanc bracket consensu estim
multipl catalyst across ophthalmolog inflamm oncolog
regeneron slew new indic market open first half recent
approv receiv us dupix chronic rhinosinus nasal polyposi
adult whose diseas control eu dupix atop dermat patient age
us eylea diabet retinopathi addit compani announc
yesterday phase treat sever atop dermat patient age met primari
secondari endpoint sbla eylea pre-fil syring also target action date
clinic catalyst regeneron start phase studi highli anticip bispecif
monoclon antibodi studi open-label potenti registr
phase studi sever type non-hodgkin lymphoma nhl includ arm
dlbcl mcl nhl patient well one group car-t failur expect
phase trial enrol patient eventu arm addit regeneron
advanc three bispecif pipelin product newest
addit co-stimulatori bispecif earli stage studi
ovarian cancer r/r mm activ enrol patient compani expect
present preliminari data end first data compani first
novel co-stimulatori bispecif emerg given timelin regeneron also
start studi libtayo cutan squamou cell carcinoma cscc adjuv juli
plan start studi cscc neoadjuv year
long-term catalyst regeneron expect announc proof-of-concept data
copd ad despit recent disappoint asthma data
show increment benefit dupix compani determin whether product
warrant phase trial indic poc data becom avail
sanofi-regeneron antibodi allianc turn posit profit
though larg anticip posit profit set import mileston sanofi-
regeneron antibodi collabor program collabor produc less
oper profit regeneron share expect antibodi program
provid meaning top-lin growth contribut regeneron start second half
year given strong dupix sale uptak disciplin expens base sale
expens forecast dupix praluent kevzara antibodi expect antibodi
allianc program gener grow
increas near-term revenu forecast pt
given latest sale trend growth outlook increas near-term revenu
forecast increas come dupix eylea us
result revenu forecast regeneron increas
larg unchang longer term remain recent consensu
consensu revenu increas expens forecast
oper expens forecast higher due
chang pro-forma ep forecast increas
lower adjust ep estim recent
consensu higher consensu later year base
chang estim chang peer compani multipl price target
decreas reiter outperform rate
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo nv
azn earn multipl ep appli current
ep estim give valu use high growth revenu multipl
similar compani nvo consensu sale
appli revenu estim give valu lastli dcf
valuat given wacc termin cash flow growth rate give present valu
averag three method current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand price pressur compani cholesterol treatment praluent lastli
compani convert rel littl revenu cash flow today histori return
cash investor ultim may undermin valu stock investor
willing continu
higher concentr formul
year age
phase result follow safeti
phase registr
phase registr
svb leerink llc equiti research compani file
brand
type event
event trial detail
date known
up/down
expect
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
svb leerink regeneron select balanc sheet cash-flow item
million
cash equival
properti plant equip net
total liabil sharehold equiti
net incom loss option expens forma
chang asset liabil
chang market secur
issuanc stock/ purchas treasuri stock
proce long-term borrow
repay long-term borrow
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap growth biotech ep multipl
ep nvo nv azn
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
sale
collabor
share count period dilut mm
guidanc
sanofi reimburs regeneron
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
fasinumab libtayo nsclc
eylea dr w/o dme libtayo basal
